LENZ Therapeutics (LENZ) Total Non-Current Liabilities (2020 - 2024)

LENZ Therapeutics (LENZ) has 5 years of Total Non-Current Liabilities data on file, last reported at $11.2 million in Q4 2024.

• On a quarterly basis, Total Non-Current Liabilities fell 42.69% year-over-year to $11.2 million in Q4 2024; TTM through Dec 2024 was $11.2 million, a 42.69% decrease from a year earlier, with the FY2024 full-year figure at $11.2 million, down 42.69% from the prior year.
• Total Non-Current Liabilities for Q4 2024 stood at $11.2 million, up from $8.7 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for LENZ reached as high as $62.9 million in Q2 2023 and fell as low as $7.9 million in Q2 2021.
• Historically, Total Non-Current Liabilities has averaged $23.6 million across 5 years, with a median of $17.0 million in 2021.
• Across the five-year window, Total Non-Current Liabilities soared 289.41% in 2023 and plunged 86.07% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $32.0 million in 2020, then sank by 44.03% to $17.9 million in 2021, then dropped by 17.53% to $14.8 million in 2022, then surged by 32.35% to $19.6 million in 2023, then tumbled by 42.69% to $11.2 million in 2024.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $11.2 million in Q4 2024, $8.7 million in Q3 2024, and $9.6 million in Q2 2024.